 A TWO-STAGE PHASE 1 DOSE ESCALATION PHARMACOKINETIC STUDY OF TARCEVA IN PATIENTS WITH STAGE IIIBIV NON-SMALL CELL LUNG CANCER WHO CONTINUE TO SMOKE AFTER FAILURE OF ONE OR TWO PRIOR CHEMOTHERAPY REGIMENS: 